Insider Selling: Glaukos (NYSE:GKOS) CEO Sells $21,498,675.00 in Stock

Glaukos Corporation (NYSE:GKOS) CEO Thomas William Burns sold 186,945 shares of the company’s stock in a transaction on Friday, January 16th. The stock was sold at an average price of $115.00, for a total transaction of $21,498,675.00. Following the completion of the transaction, the chief executive officer directly owned 153,775 shares of the company’s stock, valued at approximately $17,684,125. The trade was a 54.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Thomas William Burns also recently made the following trade(s):

• On Thursday, January 8th, Thomas William Burns sold 88,055 shares of Glaukos stock. The shares were sold at an average price of $115.00, for a total value of $10,126,325.00.

Glaukos Stock Performance

Shares of Glaukos stock opened at $125.98 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.20 and a quick ratio of 4.47. The firm has a market cap of $7.24 billion, a price-to-earnings ratio of -81.81 and a beta of 0.67. The stock’s 50-day moving average is $109.93 and its 200-day moving average is $96.15. Glaukos Corporation has a one year low of $73.16 and a one year high of $163.71.

Glaukos (NYSE:GKOS) last announced its earnings results on Wednesday, October 29th. The medical instruments supplier reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.11. Glaukos had a negative return on equity of 7.52% and a negative net margin of 18.65%.The business had revenue of $133.54 million for the quarter, compared to analyst estimates of $122.55 million. During the same quarter last year, the firm earned ($0.28) EPS. Glaukos’s revenue for the quarter was up 38.1% compared to the same quarter last year. Equities analysts predict that Glaukos Corporation will post -1.08 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Glaukos

A number of hedge funds and other institutional investors have recently bought and sold shares of GKOS. UMB Bank n.a. raised its stake in Glaukos by 102.6% in the third quarter. UMB Bank n.a. now owns 312 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 158 shares during the period. Park Place Capital Corp increased its holdings in shares of Glaukos by 68.4% during the 2nd quarter. Park Place Capital Corp now owns 399 shares of the medical instruments supplier’s stock worth $41,000 after acquiring an additional 162 shares during the last quarter. REAP Financial Group LLC bought a new stake in Glaukos in the 3rd quarter valued at $40,000. AlphaQuest LLC lifted its holdings in Glaukos by 5,754.5% during the 2nd quarter. AlphaQuest LLC now owns 644 shares of the medical instruments supplier’s stock valued at $67,000 after purchasing an additional 633 shares during the last quarter. Finally, Smartleaf Asset Management LLC boosted its position in Glaukos by 16.2% during the second quarter. Smartleaf Asset Management LLC now owns 973 shares of the medical instruments supplier’s stock worth $99,000 after purchasing an additional 136 shares during the period. Institutional investors own 99.04% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently weighed in on GKOS shares. Wells Fargo & Company raised their target price on shares of Glaukos from $120.00 to $122.00 and gave the company an “overweight” rating in a research report on Thursday, October 30th. Piper Sandler restated an “overweight” rating and issued a $165.00 price objective on shares of Glaukos in a report on Wednesday, January 14th. Citigroup upped their target price on Glaukos from $113.00 to $125.00 and gave the stock a “buy” rating in a report on Thursday, December 11th. JPMorgan Chase & Co. raised their price target on Glaukos from $110.00 to $120.00 and gave the company an “overweight” rating in a research note on Thursday, October 30th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Glaukos in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $131.38.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.